Therefore, the high expression level of PRKACB in DMD, which is similar to up-regulated PRKACB upon β-agonist treatment, is probably a result of genetic compensatory response to the muscle degeneration in DMD. Here, PRKACB is linked to Duchenne muscular dystrophy.